

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

NCT04704921

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	AbbVie
Enrollment	630 participants

Key Eligibility Criteria

Inclusion (11)

- Age e 50 years and d 89 years
 - An ETDRS BCVA letter score between d 78 and e 40 in the study eye
 - Diagnosis of subfoveal CNV secondary to AMD in the study eye previously treated with anti-VEGF
 - Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye.
 - Willing and able to provide written, signed informed consent for this study
- ... and 6 more (see full listing online)

Exclusion (18)

- CNV or macular edema in the study eye secondary to any causes other than AMD
 - Subfoveal fibrosis or atrophy in the study eye, as determined by CRC
 - Any condition in the investigator's opinion that could limit VA improvement in the study eye
 - Active or history of retinal detachment, or current retinal tear that cannot be treated, in the study eye
 - Advanced glaucoma or history of secondary glaucoma in the study eye
- ... and 13 more (see full listing online)

Locations (89 total)

Retinal Research Institute /ID# 256019, Phoenix, Arizona, United States
Barnet Dulaney Perkins Eye Center - Sun City /ID# 256055, Sun City, Arizona, United States
University of Arkansas for Medical Sciences /ID# 271290, Little Rock, Arkansas, United States
... and 86 more locations